as on November 27, 2025 at 2:29 am IST
Day's Low
Day's High
0.85%
Downside
3.98%
Upside
52 Week's Low
52 Week's High
43.83%
Downside
6.21%
Upside
Check Ascendis Pharma A/s market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$12.8B
EPS (TTM)
-3.3785
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
0PEG Ratio
0EBITDA
-133.7M
Revenue (TTM)
646.5M
Profit Margin
-36.03%
Return On Equity TTM
-818.43%
Compare market cap, revenue, PE, and other key metrics of Ascendis Pharma A/s with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $12.8B | 27.65% | NA | -36.03% | |
| BUY | $43.6B | 413.84% | -16.34 | -264.83% | |
| BUY | $58.8B | 242.77% | 1435.87 | 1.36% | |
| BUY | $110.8B | 90.63% | 30.22 | 31.35% | |
| BUY | $83.2B | 52.63% | 18.87 | 32.13% |
The Ascendis Pharma A/s stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Ascendis Pharma A/s investment value today
Current value as on today
₹1,60,098
Returns
₹60,098
(+60.1%)
Returns from Ascendis Pharma A/s Stock
₹54,156 (+54.16%)
Dollar Returns*
₹5,942 (+5.94%)
Based on 20 analysts
80.00%
Buy
20.00%
Hold
0.00%
Sell
Based on 20 analysts, 80% of analysts recommend a 'BUY' rating for Ascendis Pharma A/s. Average target price of $257.69
Get share price movements and forecasts by analysts on Ascendis Pharma A/s.
What analysts predicted
18.46%UPSIDE
Target Price
$257.69
Current Price
$210.13
Analyzed by
20 Analysts
Target
$257.69
Ascendis Pharma A/s target price $257.69, a slight upside of 18.46% compared to current price of $210.13. According to 20 analysts rating.
Search interest for Ascendis Pharma A/s Stock has increased by 108% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:108% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Revenue Rich
![]()
Revenue is up for the last 3 quarters, 100.95M → 213.63M (in $), with an average increase of 31.1% per quarter
Against Peers
![]()
In the last 3 years, Insmed Incorporated has given 1006.1% return, outperforming this stock by 930.4%
Against Peers
![]()
In the last 1 year, Insmed Incorporated has given 169.5% return, outperforming this stock by 115.4%
Price Dip
![]()
In the last 7 days, ASND stock has moved down by -0.2%
Profit Down
![]()
Netprofit is down for the last 2 quarters, -38.85M → -60.98M (in $), with an average decrease of 57.0% per quarter
| Organisation | Ascendis Pharma A/s |
| Headquarters | Tuborg Boulevard 12, Hellerup, Denmark, 2900 |
| Industry | Health Technology |
| CEO | Mr. Jan Moller Mikkelsen |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Ms. Pedersen Anni Lotte Kirstine Sonderbjerg | Executive VP, Chief Administrative Officer & Member of the Executive Board |
Mr. Mads Bodenhoff | Senior VP, Head of Finance & Principal Accounting Officer |
Mr. Flemming Steen Jensen | Executive Vice President of Product Supply & Quality |
Dr. Stina Singel M.D., Ph.D. | Executive VP & Head of Clinical Development for Oncology |
Mr. Jan Moller Mikkelsen | President, CEO, Member of Executive Board & Executive Director |
Mr. Scott T. Smith | CFO, Executive VP & Member of Executive Board |
Dr. Kennett Sprogoe Ph.D. | Executive VP and Head of Research & Product Development |
Mr. Joseph Kelly | Head of U.S. Commercial of Endocrinology |
Mr. Michael Wolff Jensen L.L.M. | Executive VP, Chief Legal Officer & Member of the Executive Board |
Mr. Chad Fugure | Vice President of Investor Relations |
Ascendis Pharma A/s share price today is $210.13 as on at the close of the market. Ascendis Pharma A/s share today touched a day high of $218.5 and a low of $208.35.
Ascendis Pharma A/s share touched a 52 week high of $223.19 on and a 52 week low of $118.03 on . Ascendis Pharma A/s stock price today i.e. is closed at $210.13,which is 5.85% down from its 52 week high and 78.03% up from its 52 week low.
Ascendis Pharma A/s market capitalisation is $0.01T as on .
Indian investors can start investing in Ascendis Pharma A/s (ASND) shares with as little as ₹89.436 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹894.36 in Ascendis Pharma A/s stock (as per the Rupee-Dollar exchange rate as on ).
Based on Ascendis Pharma A/s share’s latest price of $210.13 as on November 27, 2025 at 2:29 am IST, you will get 0.0476 shares of Ascendis Pharma A/s. Learn more about
fractional shares .
Ascendis Pharma A/s stock has given 27.65% share price returns and 20.58% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?